AURKA and small cell lung carcinoma: A targeted drug screening experiment demonstrated that SCLC patients with high MYC levels were more vulnerable to treatment with an Aurora kinase A/B (AURKA/AURKB) inhibitor, which indicated that patients with the NEUROD1 subtype may benefit from Aurora kinase inhibitors [39, 96].